Pfizer; Trials of New COVID-19 Drug Started

While vaccines are the best up-to-date option in combating the coronavirus epidemic, a new announcement from Pfizer was shared today. The company announced that the second and third phase trials of a new drug planned to be used in the treatment of COVID-19 have begun. .

According to Pfizer’s statement, the drug in development; if successful, it will stop the virus before it has a chance to replicate and prevent the development of symptoms.

Trials will be conducted on 2,660 adults:

In the announcement it shared, Pfizer stated that the trial will be performed on 2,660 healthy adult individuals over the age of 18 who share the same house with people who have previously had COVID-19 and have shown symptoms.

The drug is aimed at stopping an enzyme that allows the virus to multiply:

Mikael Dolsten, Head of Global Research, Development and Medicine at Pfizer, said, “We believe that in the fight against Covid-19, which continues to affect the world, it is necessary to develop effective treatments for people who are caught or exposed to the virus, as well as vaccines that control infection.” used.

The new drug, which aims to stop the production of an enzyme that causes the multiplication of the COVID-19 virus; It was stated that it will be used together with ritonavir, a drug widely used in HIV infections.

Before Pfizer, it was announced that Merck, a US pharmaceutical company, and Swedish Rocde, were also in the process of developing pill-form drugs to prevent and treat COVID-19 infections.